ORIC-101 for Solid Tumors

"ORIC-101 is a medication commonly employed to combat ill effects from neoplasm metastasis, as well as advanced directives, Kaposi sarcoma, and fallopian tubes cancer."

"Presently, 832 studies exploring ORIC-101 are in progress--227 of which have achieved Phase 3. Melbourne is the primary location for research concerning this medication; however, there are 45681 other sites across the globe studying its efficacy as well."

"There is minimal evidence of the safety and efficiency ORIC-101, so it has been given a 1 on our team's rating scale."

"ORIC Pharmaceuticals, the sponsor of this clinical trial, has stated that the primary goal measured over an 18-month period is determining Recommended Phase 2 Dose (RP2D). Additionally, researchers will be evaluating Abnormal Vital Signs in relation to safety and tolerability of ORIC-101 in combination with nab-pacitaxel as well as examining Area under the Curve (AUC(0-t)) regarding pharmacokinetics. Finally, they are assessing Adverse Events associated with ORIC-101 combined with nab-paclitaxel."

"According to clinicaltrials.gov, this trial is not currently recruiting participants, having been initially posted on May 2nd 2019 and last edited on September 22th 2022. That said, there are many other trials available that are actively seeking patients at the present time - 1282 in total!"

"This trial has already closed, as it was last updated on September 22nd 2022. If you are searching for alternative trials, there are 450 studies recruiting patients with tumors and 832 accepting participants for ORIC-101."

"Texas MD Anderson Cancer Centre, Virginia Cancer Specialists, and NEXT Oncology in San Antonio are among the 12 clinical trial sites for this medical experiment."